JPS6241206B2 - - Google Patents

Info

Publication number: JPS6241206B2
Authority: JP; Japan
Prior art keywords: cholesterol; monoiodohistidine; hypercholesterolemia; iodine; therapeutic agent
Prior art date: 1978-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP6782378A

Other languages

English (en)

Japanese (ja)

Other versions

JPS54160741A (en

Inventor

Tadashi Ishikawa

Hiroshi Kanzaki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NIPPON NOSAN KOGYO KK

Original Assignee

NIPPON NOSAN KOGYO KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-06-07

Filing date

1978-06-07

Publication date

1987-09-02

1978-06-07 Application filed by NIPPON NOSAN KOGYO KK filed Critical NIPPON NOSAN KOGYO KK

1978-06-07 Priority to JP6782378A priority Critical patent/JPS54160741A/ja

1979-12-19 Publication of JPS54160741A publication Critical patent/JPS54160741A/ja

1987-09-02 Publication of JPS6241206B2 publication Critical patent/JPS6241206B2/ja

Status Granted legal-status Critical Current

Links

AAKROHZJMPGWQF-VKHMYHEASA-N 5-iodo-L-histidine Chemical compound OC(=O)[C@@H](N)CC=1N=CNC=1I AAKROHZJMPGWQF-VKHMYHEASA-N 0.000 claims description 11
208000035150 Hypercholesterolemia Diseases 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
229940124597 therapeutic agent Drugs 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
230000000694 effects Effects 0.000 description 9
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 7
229910052740 iodine Inorganic materials 0.000 description 6
239000011630 iodine Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000700159 Rattus Species 0.000 description 5
235000013601 eggs Nutrition 0.000 description 5
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 3
235000013330 chicken meat Nutrition 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
239000004151 Calcium iodate Substances 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
UHWJJLGTKIWIJO-UHFFFAOYSA-L calcium iodate Chemical compound [Ca+2].[O-]I(=O)=O.[O-]I(=O)=O UHWJJLGTKIWIJO-UHFFFAOYSA-L 0.000 description 2
235000019390 calcium iodate Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
230000029142 excretion Effects 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
239000000843 powder Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241001474374 Blennius Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
230000003627 anti-cholesterol Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
150000002497 iodine compounds Chemical class 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
-1 seaweed Chemical compound 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010998 test method Methods 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP6782378A 1978-06-07 1978-06-07 Hyperchlesteremia treating agent Granted JPS54160741A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP6782378A JPS54160741A (en)	1978-06-07	1978-06-07	Hyperchlesteremia treating agent

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP6782378A JPS54160741A (en)	1978-06-07	1978-06-07	Hyperchlesteremia treating agent

Publications (2)

Publication Number	Publication Date
JPS54160741A JPS54160741A (en)	1979-12-19
JPS6241206B2 true JPS6241206B2 (cs)	1987-09-02

Family

ID=13356040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6782378A Granted JPS54160741A (en)	1978-06-07	1978-06-07	Hyperchlesteremia treating agent

Country Status (1)

Country	Link
JP (1)	JPS54160741A (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57144215A (en) *	1981-03-02	1982-09-06	Nippon Nousan Kogyo Kk	Composition for improving lipometabolism

1978
- 1978-06-07 JP JP6782378A patent/JPS54160741A/ja active Granted

Also Published As

Publication number	Publication date
JPS54160741A (en)	1979-12-19

Publication	Publication Date	Title
EP0637239B1 (en)	1999-08-11	Use of beta-hydroxy-beta-methylbutyric acid for promoting nitrogen retention in humans
EP0342956A2 (en)	1989-11-23	Use of phytic acid or its salts for the treatment of hyperlipemia, obesity and obesity-related diseases
EP0916342A1 (en)	1999-05-19	A medicament for treating obesity and improving lipid metabolism
BEST et al.	1956	Modification of abnormal serum lipid patterns in atherosclerosis by administration of sitosterol
US4410541A (en)	1983-10-18	Composite for improving lipid metabolism
JPS6299323A (ja)	1987-05-08	高脂血症剤
US5416105A (en)	1995-05-16	Treating an arteriosclerosis with glimepiride
KR100304312B1 (ko)	2001-11-22	아연이보충된전립선추출물
JPH0699310B2 (ja)	1994-12-07	アセトアルデヒド解毒剤
JPH0340010B2 (cs)	1991-06-17
JPH1053520A (ja)	1998-02-24	抗疲労剤
RU2095059C1 (ru)	1997-11-10	Способ профилактики и лечения атеросклероза
EP0215438A2 (en)	1987-03-25	Use of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine for preparing an anti-rheumatic agent
JPH0563452B2 (cs)	1993-09-10
JPH08208464A (ja)	1996-08-13	高脂血症の治療及び予防薬
US4156003A (en)	1979-05-22	Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine
Mackay et al.	1979	Haematemesis during oral aminophylline treatment
US8034833B2 (en)	2011-10-11	Phosphorus binder for treatment of renal disease
JPS61134315A (ja)	1986-06-21	解熱鎮痛剤
JP4465963B2 (ja)	2010-05-26	高脂血症の予防または改善用組成物
IE55230B1 (en)	1990-07-04	Use of a cholecalciferol derivative
JP3974213B2 (ja)	2007-09-12	骨疾患治療剤
US6441039B1 (en)	2002-08-27	Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement
JPH0143725B2 (cs)	1989-09-22
JPH07233062A (ja)	1995-09-05	人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物